Development of at-Home, Self-Administered Test for COVID19 and Respiratory Viruses

N. Kenyon, M. McCartney, E. Borras, A. Linderholm, T. Tham, K. Ramirez, R. W. Harper, C. Davis
{"title":"Development of at-Home, Self-Administered Test for COVID19 and Respiratory Viruses","authors":"N. Kenyon, M. McCartney, E. Borras, A. Linderholm, T. Tham, K. Ramirez, R. W. Harper, C. Davis","doi":"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3856","DOIUrl":null,"url":null,"abstract":"Rationale: We have proposed to develop an at-home breath collection device to diagnose and monitor patients with COVID-19. There is currently no method to track an individual's health outside of a hospital and predict if they might require clinical intervention. The present COVID19 diagnostic tests only look for direct evidence of the virus. We hypothesize that our method looks for the human body's response to infection. This allows us to not only determine whether an individual is infected or not, but also determine the severity of their health condition through chemical analysis of their metabolism. T Methods: COVID-19 infected patients are given a device that allows them to safely, non-invasively, and painlessly collect their own breath samples, which we are screening for not only COVID- 19 infection, but for other common respiratory viral infections, such as other coronaviruses, rhinovirus and influenza. We will compare the breath biomarkers of influenza with COVID-19 with that of our identified pattern of influenza. We are assessing the sensitivity of our test to diagnose COVID-19 and the specificity to not only diagnose COVID-19 from typical influenzas and rhinoviruses, but also the specificity to diagnose COVID-19 in patients with co-infections of other pulmonary viruses. Nasopharyngeal swab will be the gold standard. Results: We have collected exhaled breath condensate samples from patients with COVI19 infection. The device is can be used safely by the patient and does not require the participation of research coordinators during the breath collection phase. Symptomatic patients are able to use the device without excessive shortness of breath or other effects. The mass spectroscopy screening of the breath samples will look at a panel of eicosanoid biomarkers related to pulmonary infection and markers of oxidative stress. Patterns are being compared to prior breath profiles found with influenza infection. Conclusion: Our breath collection device could provide an “alarm” for individuals who are potentially facing a stark decline in health and should preemptively move into a hospital or clinical setting for closer monitoring. Because this method screens for a myriad of respiratory viruses and of pulmonary health simultaneously, its impact would extend far beyond the current COVID-19 pandemic.","PeriodicalId":23203,"journal":{"name":"TP92. TP092 CLINICAL ADVANCES IN SARS-COV-2 AND COVID-19","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP92. TP092 CLINICAL ADVANCES IN SARS-COV-2 AND COVID-19","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3856","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale: We have proposed to develop an at-home breath collection device to diagnose and monitor patients with COVID-19. There is currently no method to track an individual's health outside of a hospital and predict if they might require clinical intervention. The present COVID19 diagnostic tests only look for direct evidence of the virus. We hypothesize that our method looks for the human body's response to infection. This allows us to not only determine whether an individual is infected or not, but also determine the severity of their health condition through chemical analysis of their metabolism. T Methods: COVID-19 infected patients are given a device that allows them to safely, non-invasively, and painlessly collect their own breath samples, which we are screening for not only COVID- 19 infection, but for other common respiratory viral infections, such as other coronaviruses, rhinovirus and influenza. We will compare the breath biomarkers of influenza with COVID-19 with that of our identified pattern of influenza. We are assessing the sensitivity of our test to diagnose COVID-19 and the specificity to not only diagnose COVID-19 from typical influenzas and rhinoviruses, but also the specificity to diagnose COVID-19 in patients with co-infections of other pulmonary viruses. Nasopharyngeal swab will be the gold standard. Results: We have collected exhaled breath condensate samples from patients with COVI19 infection. The device is can be used safely by the patient and does not require the participation of research coordinators during the breath collection phase. Symptomatic patients are able to use the device without excessive shortness of breath or other effects. The mass spectroscopy screening of the breath samples will look at a panel of eicosanoid biomarkers related to pulmonary infection and markers of oxidative stress. Patterns are being compared to prior breath profiles found with influenza infection. Conclusion: Our breath collection device could provide an “alarm” for individuals who are potentially facing a stark decline in health and should preemptively move into a hospital or clinical setting for closer monitoring. Because this method screens for a myriad of respiratory viruses and of pulmonary health simultaneously, its impact would extend far beyond the current COVID-19 pandemic.
新冠病毒和呼吸道病毒居家自用检测方法的开发
理由:我们建议开发一种家用呼吸采集装置来诊断和监测COVID-19患者。目前还没有办法在医院外追踪个人的健康状况,并预测他们是否需要临床干预。目前的covid - 19诊断检测仅寻找该病毒的直接证据。我们假设我们的方法寻找人体对感染的反应。这使我们不仅可以确定一个人是否被感染,还可以通过对其新陈代谢的化学分析来确定其健康状况的严重程度。方法:为COVID-19感染的患者提供一种设备,使他们能够安全、无创、无痛地收集自己的呼吸样本,我们不仅筛查COVID-19感染,还筛查其他常见的呼吸道病毒感染,如其他冠状病毒、鼻病毒和流感。我们将比较COVID-19流感的呼吸生物标志物与我们确定的流感模式。我们正在评估我们的检测方法诊断COVID-19的敏感性,以及不仅能从典型流感病毒和鼻病毒中诊断COVID-19的特异性,还能在合并感染其他肺部病毒的患者中诊断COVID-19的特异性。鼻咽拭子将是金标准。结果:采集到COVI19感染患者呼出液样本。该装置可以由患者安全使用,并且在呼吸收集阶段不需要研究协调员的参与。有症状的患者可以使用该设备,而不会出现过度的呼吸短促或其他影响。呼吸样本的质谱筛选将着眼于一组与肺部感染和氧化应激标志物相关的类二十烷生物标志物。正在与流感感染患者先前的呼吸特征进行比较。结论:我们的呼吸收集装置可以为那些可能面临健康状况急剧下降的个人提供“警报”,应该提前进入医院或临床环境进行更密切的监测。由于这种方法同时筛查无数呼吸道病毒和肺部健康,其影响将远远超出当前的COVID-19大流行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信